| Interest in Lpath Inc. (LPTN) has been rising along with share prices. The stock closed nearly 7% higher on Thursday and capped off another positive session. The emerging biotech had seen considerable interest from biotech investors and speculators before a temporary halt in the company's iSONEP trial was announced in January due to no fault of either Lpath or their clinical partner Pfizer Pharmaceuticals. The FDA had targeted Formatech, Inc., a vendor/contractor which was providing fill/finish servi...continued LPTN vegf angiogenesis pharmaceuticals |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment